BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37962553)

  • 1. Steroid profile in patients with breast cancer and in mice treated with mifepristone.
    Elía A; Saldain L; Lovisi S; Martínez Vazquez P; Burruchaga J; Lamb CA; Lüthy IA; Diez F; Homer NZM; Andrew R; Rojas P; Lanari C
    Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 37962553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
    Rojas PA; May M; Sequeira GR; Elia A; Alvarez M; Martínez P; Gonzalez P; Hewitt S; He X; Perou CM; Molinolo A; Gibbons L; Abba MC; Gass H; Lanari C
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.
    Elía A; Saldain L; Vanzulli SI; Helguero LA; Lamb CA; Fabris V; Pataccini G; Martínez-Vazquez P; Burruchaga J; Caillet-Bois I; Spengler E; Acosta Haab G; Liguori M; Castets A; Lovisi S; Abascal MF; Novaro V; Sánchez J; Muñoz J; Belizán JM; Abba MC; Gass H; Rojas P; Lanari C
    Clin Cancer Res; 2023 Mar; 29(5):866-877. PubMed ID: 36269797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
    Wargon V; Riggio M; Giulianelli S; Sequeira GR; Rojas P; May M; Polo ML; Gorostiaga MA; Jacobsen B; Molinolo A; Novaro V; Lanari C
    Int J Cancer; 2015 Jun; 136(11):2680-92. PubMed ID: 25363551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line.
    Khan JA; Bellance C; Guiochon-Mantel A; Lombès M; Loosfelt H
    PLoS One; 2012; 7(9):e45993. PubMed ID: 23029355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.
    Sequeira G; Vanzulli SI; Rojas P; Lamb C; Colombo L; May M; Molinolo A; Lanari C
    Oncotarget; 2014 May; 5(10):3246-60. PubMed ID: 24912774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
    Ronchi C; Brisken C
    Clin Cancer Res; 2023 Mar; 29(5):833-834. PubMed ID: 36547665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas.
    Wargon V; Fernandez SV; Goin M; Giulianelli S; Russo J; Lanari C
    Breast Cancer Res Treat; 2011 Apr; 126(2):319-32. PubMed ID: 20440553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
    Abascal MF; Elia A; Alvarez M; Pataccini G; Sequeira G; Riggio M; Figueroa V; Lamb CA; Rojas PA; Spengler E; Martínez-Vazquez P; Burruchaga J; Liguori M; Sahores A; Wargon V; Molinolo A; Hewitt S; Lombes M; Sartorius C; Vanzulli SI; Giulianelli S; Lanari C
    Int J Cancer; 2022 May; 150(9):1481-1496. PubMed ID: 34935137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization.
    Khan JA; Amazit L; Bellance C; Guiochon-Mantel A; Lombès M; Loosfelt H
    Mol Endocrinol; 2011 Oct; 25(10):1710-24. PubMed ID: 21816898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
    Montecchia MF; Lamb C; Molinolo AA; Luthy IA; Pazos P; Charreau E; Vanzulli S; Lanari C
    J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):11-21. PubMed ID: 10215033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice.
    El Etreby MF; Liang Y
    Breast Cancer Res Treat; 1998 May; 49(2):109-17. PubMed ID: 9696393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitive effects of mifepristone on growth of breast cancer: experiment with animal model].
    Tian XS; Zhou WH; Wu GJ; Sun JZ; Cong MH
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):559-63. PubMed ID: 18649774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?
    Horwitz KB
    Endocr Rev; 1992 May; 13(2):146-63. PubMed ID: 1618161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of two antiprogestins on early pregnancy in the long-tailed macaque (Macaca fascicularis).
    Tarantal AF; Hendrickx AG; Matlin SA; Lasley BL; Gu QQ; Thomas CA; Vince PM; Van Look PF
    Contraception; 1996 Aug; 54(2):107-15. PubMed ID: 8842588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.
    Wang H; Lee EW; Zhou L; Leung PC; Ross DD; Unadkat JD; Mao Q
    Mol Pharmacol; 2008 Mar; 73(3):845-54. PubMed ID: 18042733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas.
    Wargon V; Helguero LA; Bolado J; Rojas P; Novaro V; Molinolo A; Lanari C
    Breast Cancer Res Treat; 2009 Aug; 116(3):449-60. PubMed ID: 18677559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
    Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
    Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.
    Altinoz MA; Ozpinar A; Elmaci I
    Neurosurg Rev; 2019 Jun; 42(2):351-369. PubMed ID: 29453736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
    Cameron ST; Critchley HO; Buckley CH; Kelly RW; Baird DT
    Fertil Steril; 1997 Jun; 67(6):1046-53. PubMed ID: 9176442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.